Heart Failure Clinical Trials in Philadelphia, Pennsylvania

19 studies are recruiting for heart failure in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Philadelphia, PA Investigative Site 10068, Philadelphia, Pennsylvania

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

3. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

   Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Philadelphia, PA Investigative Site CON-10068, Philadelphia, Pennsylvania

   Locations

   140 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06024746 on ClinicalTrials.gov

4. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

5. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   Children's Hospital of Philadelphia (CHOP) ( Site 0004), Philadelphia, Pennsylvania

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

6. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine), Philadelphia, Pennsylvania

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

7. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

   Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Penn Presbyterian Medical Center, Philadelphia, Pennsylvania

   Locations

   50 in total

   Run by

   Procyrion

   See if you can join NCT05677100 on ClinicalTrials.gov

8. NORM-HF Pivotal Study

   This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF event…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   9 in total

   Run by

   Foundry Innovation & Research 1, Limited (FIRE1)

   See if you can join NCT07574593 on ClinicalTrials.gov

9. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Philadelphia, Pennsylvania

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

10. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Thomas Jefferson University, Philadelphia, Pennsylvania

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

11. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Penn Presbyterian Medical Center, Philadelphia, Pennsylvania

    Locations

    105 in total

    Run by

    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

12. Quantifying New Heart Muscle Cells

    Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease a…

    Stage

    Not phased

    Ages

    0 to 1

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06587165 on ClinicalTrials.gov

13. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    68 in total

    Run by

    Abbott Medical Devices

    See if you can join NCT06526195 on ClinicalTrials.gov

14. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

15. HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

    HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes …

    Stage

    Not phased

    Ages

    30 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    6 in total

    Run by

    Northwestern University

    See if you can join NCT05873634 on ClinicalTrials.gov

16. Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

    The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new trea…

    Stage

    Not phased

    Ages

    30 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    6 in total

    Run by

    Northwestern University

    See if you can join NCT06517186 on ClinicalTrials.gov

17. His-Bundle Corrective Pacing in Heart Failure

    The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    14 in total

    Run by

    University of Rochester

    See if you can join NCT05265520 on ClinicalTrials.gov

18. Left vs Left Randomized Clinical Trial

    The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications an…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    71 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT05650658 on ClinicalTrials.gov

19. Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation

    The goal of this clinical trial is to evaluate the effects of a home-based exercise program using mobile technology on physical activity and capacity, frailty and muscle mass, and quality of life in patients with a newly implanted HeartMate 3 left ventricular assist device (HM3 LVAD). Researchers w…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    4 in total

    Run by

    University of Pennsylvania

    See if you can join NCT06291922 on ClinicalTrials.gov